Cipla Ltd, an Indian Pharma giant has scaled up the production of Covid-19 medication Remdesivir, it announced on Tuesday.
In a statement to Reuters, the company said, “We have scaled up the production of Remdesivir by 2 times from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network.”
Cipla is working with authorities to restrict Remdesivir supply just to hospitals and places with a high burden of severe COVID-19 cases, it added.
The Central Government has fast-tracked emergency approval for foreign-produced jabs that have been granted similar clearances in other countries.
The decision came on Tuesday after NEGVAC recommended that COVID-19 vaccines which have been granted emergency approval for restricted use by authorities in the US, Europe, the UK, Japan or which are listed in the WHO Emergency Use Listing may be granted emergency use approval in India, mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial as per the provisions prescribed under Second Schedule of the New Drugs & Clinical Trials Rules 2019.
Accroding to a press release by the Union Ministry of Health, “The first 100 beneficiaries of such foreign vaccines shall be assessed for seven days for safety outcomes before it is rolled out for further immunization programme within the country. The Union Government, after due consideration, has accepted the recommendation of NEGVAC.”
Dr Harsh Vardhan, talking how human health could not be seen in isolation anymore, stressed on the need of ‘One Health’ approach, especially during COVID. He announced the creation of an Eco-Health initiative for India which will be supported by National Institute of One Health.
He elucidated that 64 per cent of all infectious diseases which have emerged between 1973 and 1994 had aetiology which was zoonotic in nature. While talking about zoonotic viruses, Harsh Vardhan said India is one of the four global hotspots for the emergence of zoonotic diseases and added that “we are struggling even after 15 months”.
A notice has been released by the Drugs Controller General of India ordering all the States and UTs to perform special surveillance and inquiry to avoid hoarding, black marketing and overcharging for Remdesivir.
In addition to this, the DCGI wrote to all the states and UTs that, “You are requested to instruct your enforcement staff immediately to keep strict and vigil, especially at sensitive places and to take stringent action against hoarding/black marketing/overcharging for Remdesivir, by conducting a special drive of monitoring and investigation, so that any such incidence for the drug is prevented.”
In the view of the alarming surge of coronavirus cases in the national capital, the Delhi government on Monday has declared at least 14 big private hospitals as fully Covid-care centres on Monday. The decision was announced hours after the Delhi Chief Minister Arvind Kejriwal chaired an emergency meeting in view of Covid-19 situation in the capital today
Those hospitals which are declared as fully Covid hospitals include Indraprastha Apollo Hospital, Sir Ganga Ram, Holy Family, Maharaja Agarsen Hospital (Punjabi Bagh), Max Hospital (Shalimar Bagh), Fortis Hospital (Shalimar Bagh), Venkateshwar Hospital, Sri Balaji Action Medical Institute, Jaipur Golden Hospital, Mata Chanan Devi Hospital, Pushpawati Singhania Research Institute, Manipal Hospital and Saroj Super Specialty Hospital.
The Delhi Government has also directed that all these hospitals declared as fully Covid hospitals will not admit any non-Covid patients till further order.
“In order to augment the bed capacity for Cvod-19 patients in view of unprecedented surge of coronavirus cases in past few days, 14 private hospitals are declared as full Covid hospitals and are directed that henceforth these hospitals shall not admit any non-Covid medical/ surgical patients till further order,” an order issued by the Delhi government reads.
Union Minister Nitin Gadkari on Monday directed Nagpur District Collector Ravindra Thackeray to distribute Remdesivir injections received through Mylan India and Sun Pharma to other districts of Vidarbha in Maharashtra, reports ANI.
Gadhkari’s office informed that the minister has directed to distribute Remdesivir injections received through Mylan India and Sun Pharma to other districts of Vidarbha as well.
ANI further reports that all domestic manufacturers of Remdesivir have been advised to display on their website, details of their stocklists/distributors to facilitate access to the drug. The drug inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing. The State Health Secretaries will review this with the Drug Inspectors of their respective State/UTs.
India reported over 1.60 lakh new COVID-19 cases and 904 deaths in the last 24 hours, according to the Union Health Ministry.
New research shows, about a third of COVID-19 patients patients go on to develop “long haul” neurological or psychiatric conditions months after being infected. Such cases are coming into notice around the world.
Researchers reported, that the findings suggest a link between COVID-19 and a higher risk for later mental health and n
eurological disorders.
It found that 34% of patients were diagnosed with such disorders in the six months after infection with the new coronavirus. The new analysis of data from more than 236,000 COVID-19 survivors focused on 14; neurological and mental health disorders.
Most commonly, these disorders ranged from anxiety disorders to substance misuse disorders, insomnia, brain hemorrhage, stroke, and (much more rarely) dementia.
For 13% of those patients, it was their first such diagnosis.
“Sadly, many of the disorders identified in this study tend to be chronic or recurrent, so we can anticipate that the impact of COVID-19 could be with us for many years,” Jonathan Rogers, of University College London, wrote in an editorial accompanying the new study. Both were published April 6 in The Lancet Psychiatry.
About a third did go on to experience some kind of neurological or mental health issue within six months of their coronavirus infection. Anxiety (17%), mood disorders (14%), substance abuse disorders (7%) and insomnia (5%) were the most commonly diagnosed disorders, the team said.
Overall rates of neurological problems were much lower, including 0.6% for brain hemorrhage, 2.1% for ischemic stroke, and 0.7% for dementia.
Neurological conditions were more common in patients who had been seriously ill with COVID-19. For example, among patients admitted to intensive care, 7% had a stroke and almost 2% were diagnosed with dementia, Harrison’s group reported.
Neurological and mental health diagnoses were more common in COVID-19 patients than in flu or respiratory tract infection patients over the same time period. That suggests COVID-19 has an impact that’s unique among viral infections, the study authors said.
“These are real-world data from a large number of patients. They confirm the high rates of psychiatric diagnoses after COVID-19, and show that serious disorders affecting the nervous system [such as stroke and dementia] occur, too,” Harrison said in a journal news release. “While the latter are much rarer, they are significant, especially in those who had severe COVID-19.”
Just how COVID-19 affects the brain remains unclear. “We now need to see what happens beyond six months. The study cannot reveal the mechanisms involved, but does point to the need for urgent research to identify these, with a view to preventing or treating them,” study co-author Max Taquet, from the University of Oxford, said in the release.
According to Rogove, the study highlights an “increased risk for neurological disease and diagnosis in COVID-19 infected persons with further increased risk in hospitalized and critically ill COVID-19 infected patients.”
All of this means “there will be a great need for more neurological care following COVID infection,” Rogove added.
Brittany LeMonda is senior neuropsychologist at Lenox Hill Hospital in New York City. Reading over the findings, she theorized that “the virus may ‘unmask’ or accelerate the presentation of certain underlying psychiatric and neurologic conditions.”
In other words, “it’s possible … that an individual has underlying risk factors predisposing them to development of these conditions and the virus stresses the system enough so that these symptoms become clinically significant,” LeMonda said.